| Species |
Human |
| Protein Construction |
TPBG/5T4 (Ser32-Ser355)
Accession # Q13641 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TPBG/5T4 hFc Chimera, Human at 0.5μg/ml (100μl/Well) on the plate can bind Biotinylated AntiTPBG Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
62.08 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 75-105 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The oncofetal tumor-associated antigen 5T4 (TBGP) has been linked with CSC properties in several different malignancies. 5T4 has functional attributes that are relevant to the spread of tumors including through EMT, CXCR4/CXCL12, Wnt, and Hippo pathways which may all contribute through the mobilization of CSCs. |
| Synonyms |
M6P1; 5T4AG; WAIF1; TPBG; 5T4 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
